BEAT®: A Platform To Advance Developable Multispecific Therapeutic Antibodies To The Clinic
- The flexible BEAT® platform enables 5 or more functional modules to be combined into a single molecule with excellent manufacturability and developability
- This platform has been clinically validated by demonstrating superior efficacy, low immunogenicity in humans and good pharmacokinetics
- The biophysical plus functional screening and precision engineering required to generate MultispecificTM immune engagers advancing to the clinic to treat haematological and solid cancers will be described.